AbbVie stock at EUR 254.75, down 1.14% before Xetra
Published on 11/04/2026 at 08:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAbbVie premarket focus
- AbbVie develops medicines through research and development and external collaborations.
- The company says it works with more than 250 active external innovation partners.
AbbVie stock traded at EUR 254.75 on Lang & Schwarz at 08:43 CET on Wednesday, November 4, 2026, 1.14 percent below the Xetra close of Tuesday, November 3, 2026 at EUR 257.70.
Investors can follow the real-time quote of AbbVie stock as the European session develops. The premarket indication places the shares below the latest Xetra closing level, while the next regular Xetra session will provide the market's official German trading reference.
Research remains central
AbbVie presents pharmaceutical research and development as a central part of its business. On its corporate website, the company says it works with more than 250 active external innovation partners to support the discovery and development of medicines. AbbVie describes collaboration across disciplines as part of its research model.
The broader market backdrop can be followed through the S&P 500.
Further developments for investors are collected in more news and analyses on AbbVie stock.
